

IQoro (neuromuscular treatment device)

KEY POINTS

- IQoro is a neuromuscular self-treatment device that treats the underlying cause of reflux by restoring the dysfunctional musculature in the diaphragm.¹ In patients with dysphagia, it restores muscle strength and neurological control to enable a normal swallow.² Unlike other treatments, IQoro is able to strengthen muscles under the involuntary control of the autonomic nervous system.¹ IQoro is now available to prescribe on the NHS.³
- NICE notes the intended place of IQoro in therapy for people with hiatus hernia is as an alternative to long-term proton pump inhibitor (PPI) treatment or laparoscopic fundoplication surgery.³ In patients with dysphagia, IQoro can restore normal swallowing even in those with chronic dysphagia receiving enteral nutrition, allowing them to return to an oral diet.⁴
- To support effective use of IQoro, MYoroface AB provides a website with information, videos and advice for healthcare professionals and patients, as well as a customer helpdesk and an optional app. Peer support is available via a Facebook IQoro user group.
- NICE has issued a medtech innovation briefing on IQoro as an alternative to long-term PPI treatment or laparoscopic fundoplication for hiatus hernia. In three studies in patients with hiatus hernia, MYoroface AB reported to NICE that 93%, 58% and 61% of patients, respectively, were able to cease all PPI medication after IQoro training and the remainder 'mostly reduced dose and intake frequency'.³



IQoro is a neuromuscular self-treatment device that treats the underlying cause of reflux and dysphagia.

- Ten published peer-reviewed studies, including a randomised controlled trial, support the efficacy of IQoro in treating dysphagia and reflux-based diseases.⁵
- A service evaluation at an NHS Trust has demonstrated the effectiveness of IQoro for treating dysphagia in patients in acute and community care settings (n=21), with significant improvements in dysphagia symptoms, impact and quality of life; in addition, 40% of participants receiving enteral feeding were able to return to an oral diet.⁴

See overleaf for references

For more information contact MYoroface on 0808 175 0297 or info@iqoro.com

Initiated, funded and reviewed by MYoroface AB.

Content created by Haymarket Media Group.



IQoro (neuromuscular treatment device)

COMPANY

MYoroface AB

LEGAL CATEGORY

Medical device

PRESENTATION

Neuromuscular training device, adult or child size (up to approx 10-12 years), 1 plus storage case and instruction manual=£121.00.

INDICATIONS

Reflux-based diseases (eg, GORD, laryngopharyngeal reflux, silent reflux).
Dysphagia, drooling, facial weakness.

USAGE

Usually 3 x 10-second pulls, repeated three times daily; preferably before mealtimes in patients with dysphagia.

CONTRAINDICATIONS

Trigeminal neuralgia, paraoesophageal hernia, achalasia cardiaea.



WARNINGS

Tinnitus, peripheral facial palsy and complex dysphagia may require gradual increase in treatment intensity. Risk of delayed-onset muscle soreness; warn patient. In patients with hiatus hernia, undiagnosed oesophageal irritation may manifest as oral bleeding with use of IQoro; advise patient this is not caused by the device. Incorrect technique may cause gum irritation.

The above is a MIMS summary of the IQoro product information.

References

1. Hägg M, Franzén F. Introducing an innovative oral neuromuscular treatment of the underlying reason for reflux caused by hiatus hernia: an aggravating factor in esophagitis. In Esophagitis and Gastritis (eds Neri V, Ahmed M) IntechOpen: 2021. Available at: <https://www.intechopen.com/chapters/75980> (accessed 23 March 2022).
2. Drug Tariff May 2022. Available at: nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff (accessed 1 May 2022).
3. NICE Medtech Innovation Briefing MIB176. IQoro for hiatus hernia. Published 6 March 2019. Available at: nice.org.uk/advice/mib176/chapter/Summary (accessed 23 March 2022).
4. Exell R, McBain H, Tuvey S et al. IQoro dysphagia therapy within an NHS SLT caseload: A service evaluation. Poster presented at Virtual 14th UK Stroke Forum, December 2020. Available at clinicians.iqoro.com/evidence/service-evaluation/ (accessed 11 April 2022).
5. MYoroface AB. 'Summary of studies.' Available at clinicians.iqoro.com/wp-content/uploads/sites/10/2022/04/Summary-of-Studies-IQoro-SoS-1-18.pdf (accessed 11 April 2022).